The DOI matches its Crossref record.
AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: A report from the Children's Oncology Group
Open accessAbstract
BACKGROUND: The development of antigen‐targeted therapies may provide additional options to improve outcomes in children with acute myeloid leukemia (AML). The Children's Oncology Group AAML03P1 trial sought to determine the safety of adding 2 doses of gemtuzumab ozogamicin, a humanized anti‐CD33 antibody‐targeted agent, to intensive chemotherapy during remission induction and postremission intensification for children with de novo AML. METHODS: AAML03P1 enrolled 350 children with previously untreated AML. Patients with a matched family donor received 3 courses of chemotherapy followed by hematopoietic stem cell transplantation; those without a matched family donor received 5 courses of chemotherapy. Gemtuzumab ozogamicin 3 mg/m 2/dose was administered on Day 6 of Course 1 and Day 7 of Course 4. RESULTS: Toxicities observed in all courses of therapy were typical of AML chemotherapy regimens, with infection being most common. Patients achieved a complete remission rate of 83% after 1 course and 87% after 2 courses. The mortality rate was 1.5% after the first gemtuzumab ozogamicin‐containing induction course and 2.6% after 2 induction courses. The 3‐year event‐free survival and overall survival rates were 53 ± 6% and 66 ± 5%, respectively. CONCLUSIONS: This trial determined that it is safe and feasible to include gemtuzumab ozogamicin in combination with intensive chemotherapy. The survival rates compare favorably with the recently published results of clinical trials worldwide. Cancer 2012;. © 2011 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Bolouri, H., Farrar, J. E., Triche, T., Ries, R. E., Lim, E. L., Alonzo, T. A., Ma, Y., Moore, R., Mungall, A. J., Marra, M. A., et al. (2018) · Nature Medicine · doi:10.1038/nm.4439 · Cited by 848
Self-citationGamis, A. S., Alonzo, T. A., Meshinchi, S., Sung, L., Gerbing, R. B., Raimondi, S. C., Hirsch, B. A., Kahwash, S. B., Heerema-McKenney, A., Winter, L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.3628 · Cited by 486
Self-citationLoken, M. R., Alonzo, T. A., Pardo, L., Gerbing, R. B., Raimondi, S. C., Hirsch, B. A., Ho, P. A., Franklin, J., Cooper, T. M., Gamis, A. S., et al. (2012) · Blood · doi:10.1182/blood-2012-02-408336 · Cited by 297
Self-citationConneely, S. E., McAtee, C. L., Gupta, R., Lubega, J., Scheurer, M. E., & Rau, R. E. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004735 · Cited by 31
Metadata
- Authors
- Cooper, T. M., Franklin, J., Gerbing, R. B., Alonzo, T. A., Hurwitz, C., Raimondi, S. C., Hirsch, B., Smith, F. O., Mathew, P., Arceci, R. J., Feusner, J., Iannone, R., Lavey, R. S., Meshinchi, S., & Gamis, A.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2011-07-15
- Volume
- 118
- Issue
- 3
- Pages
- 761-769
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1590009046
- Cited by
- 199
- References
- 0
- FWCI
- 10.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: A report from the Children's Oncology Group. https://app.cochat.ai/papers/10.1002/cncr.26190
- The paper
- Cooper, T. M., Franklin, J., Gerbing, R. B., Alonzo, T. A., Hurwitz, C., Raimondi, S. C., Hirsch, B., Smith, F. O., Mathew, P., Arceci, R. J., Feusner, J., Iannone, R., Lavey, R. S., Meshinchi, S., & Gamis, A. (2012). AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: A report from the Children's Oncology Group. Cancer. https://doi.org/10.1002/cncr.26190
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
